<DOC>
	<DOCNO>NCT00075764</DOCNO>
	<brief_summary>RATIONALE : Estrogen stimulate growth breast cancer cell . Hormone therapy use drug anastrozole fulvestrant may fight breast cancer block use estrogen . It yet know whether anastrozole effective without fulvestrant treat breast cancer . PURPOSE : This randomized phase III trial study give anastrozole together fulvestrant see well work compare anastrozole alone first-line therapy treat postmenopausal woman metastatic breast cancer .</brief_summary>
	<brief_title>S0226 Anastrozole With Without Fulvestrant First-Line Therapy Postmenopausal Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare time tumor progression postmenopausal woman metastatic breast cancer treat anastrozole without fulvestrant first-line therapy . - Compare clinical benefit ( complete partial response , confirm unconfirmed , stable disease ≥ 24 week ) overall survival patient treat regimen . - Compare adverse event patient treat regimen . - Determine prognostic significance estrogen receptor positivity HER2/neu status patient treat regimen . - Determine parameter estrogen clinical pharmacology estrogen level patient treat regimen . - Compare anastrozole plasma level 8 , 16 , 24 week patient treat regimen ( close 4/16/2009 ) . - Compare estradiol serum level 8 , 16 , 24 week patient treat regimen ( close 4/16/2009 ) . OUTLINE : This randomize , multicenter study . Patients stratify accord prior adjuvant tamoxifen therapy ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral anastrozole daily day 1-28 . - Arm II : Patients receive oral anastrozole arm I . Patients also receive fulvestrant intramuscularly day 1 , 14 , 28 course 1 day 28 subsequent course . In arm , course repeat every 28 day absence disease progression unacceptable toxicity . Patients follow 4 year . PROJECTED ACCRUAL : A total 690 patient ( 345 per treatment arm ) accrue study within 3 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer meet 1 follow criterion : Metastatic disease ( M1 ) Multiple sit new disease clinically obvious metastatic disease ( e.g. , multiple sit new osseous disease ) Measurable nonmeasurable disease No known brain CNS metastases Hormone receptor status : Estrogenreceptor positive* AND/OR Progesteronereceptor positive* NOTE : *Positivity define estrogen bind &gt; 10 fmol/mg cytosol protein ligand bind assay positive immunohistochemistry PATIENT CHARACTERISTICS : Age Not specify Sex Female Menopausal status Postmenopausal , define 1 following : Prior bilateral oophorectomy More 12 month since last menstrual period prior hysterectomy At least 55 year age prior hysterectomy Under 55 year age prior hysterectomy without oophorectomy estradiol folliclestimulating hormone level consistent menopause Performance status Zubrod 02 Life expectancy Not specify Hematopoietic No bleed diathesis ( e.g. , disseminate intravascular coagulation clot factor deficiency ) Hepatic INR ≤ 1.6 Renal Not specify Other HIV negative No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer currently complete remission PRIOR CONCURRENT THERAPY : Biologic therapy No prior immunotherapy recurrent metastatic disease Chemotherapy No prior chemotherapy recurrent metastatic disease More 12 month since prior adjuvant neoadjuvant chemotherapy No concurrent chemotherapy malignancy Endocrine therapy Prior adjuvant hormonal therapy allow At least 12 month since prior adjuvant luteinizing hormonereleasing hormone ( LHRH ) analogues Menstrual period must resume since LHRH therapy More 12 month since prior adjuvant neoadjuvant aromatase inhibitor ( e.g. , anastrozole , letrozole , exemestane ) More 12 month since prior fulvestrant No prior hormonal therapy recurrent metastatic disease No concurrent hormonal therapy malignancy No concurrent hormone replacement therapy Radiotherapy Not specify Surgery Not specify Other No longterm anticoagulant therapy ( except antiplatelet therapy )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>